A Cost-Effectiveness Analysis of the Effect of Pregabalin Versus Usual Care in the Treatment of Refractory Neuropathic Pain in Routine Medical Practice in Spain

Pain Medicine (United States)

Volumn 13, Issue 5, 2012, Pages 699-710

  de Salas Cansado, Marina ^a   Pérez, Concepción ^b   Saldaña, María T ^c   Navarro, Ana ^d   Rejas, Javier ^e  

^a TFS People   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c Primary Care Health Centre Raices   (Spain)

^d Puerta Del Ángel Primary Care Center   (Spain)

^e PFIZER INC   (United States)

Author keywords

Cost Effectiveness; Neuropathic Pain; Pregabalin; QALY, Usual Care; Refractory Patients

Indexed keywords

PREGABALIN;

ACUPUNCTURE; ADULT; AGE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ELECTROSTIMULATION THERAPY; FEMALE; HEALTH CARE; HUMAN; HYDROTHERAPY; IONTOPHORESIS; MAGNETOTHERAPY; MAJOR CLINICAL STUDY; MALE; MICROWAVE THERAPY; NEUROPATHIC PAIN; PHYSIOTHERAPY; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SPAIN; SPINAL CORD STIMULATION; TRANSCUTANEOUS NERVE STIMULATION; VISUAL ANALOG SCALE;

EID: 84861214361     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01375.x     Document Type: Article

References (47)

1. Treede RD, Jensen TS, Campbell JN, etal. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5.
2. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: A practical guide for the clinician. CMAJ 2006;175:265-75.
3. Bowsher D. Neurogenic pain syndromes and their management. Br Med Bull 1991;47:644-66.
4. Smith TE, Chong MS. Neuropathic pain. Hosp Med 2000;6:760-6.
5. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5:143-9.
6. Lachaine J, Gordon A, Choiniere M, etal. Painful neuropathic disorders: An analysis of the Régie de l'Assurance Maladie du Québec database. Pain Res Manag 2007;12:31-7.
7. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: Results from a nationally representative sample. Pain 2004;111:77-83.
8. Gore M, Brandenburg NA, Dukes E, etal. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005;30:374-85.
9. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: A novel treatment approach. Clin J Pain 2007;23:15-22.
10. Gallagher RM, Verma S. Managing pain and comorbid depression: A public health challenge. Semin Clin Neuropsychiatry 1999;4:203-20.
11. Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev 2004;8:119-32.
12. Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: A cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 2006;20:26-33.
13. Tolle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: Results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. Pain Pract 2006;6:153-60.
14. van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006;35:132-7.
15. Schmader KE. Epidemiology and impact on quality of life of post-herpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-4.
16. Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007;23:143-9.
17. Gálvez R, Marsal C, Vidal J, Ruiz M, Rejas J. Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions. Eur J Pain 2007;11:244-55.
18. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: Results from a cross-sectional survey. Eur J Pain 2006;10:127-35.
19. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: The patients' perspectives. J Pain 2006;7:892-900.
20. Currie CJ, Poole CD, Woehl A, etal. The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med 2007;24:187-94.
21. Rodríguez MJ, García AJ. A registry of the aetiology and costs of neuropathic pain in pain clinics: Results of the registry of aetiologies and costs (REC) in neuropathic Pain disorders study. Clin Drug Investig 2007;27:771-82.
22. Gallagher RM. Neuropathic pain: The global challenge. Pain Med 2004;5(suppl 1):S1-2.
23. Attal N, Cruccu G, Haanpää M, etal. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69.
24. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005;118:289-305.
25. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: A novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007;29:26-48.
26. Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: Current evidence and future directions. Curr Opin Anaesthesiol 2007;20:456-72.
27. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-63.
28. Dworkin RH, Corbin AE, Young JP Jr, etal. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2003;60:1274-83.
29. Sabatowski R, Galvez R, Cherry DA, etal. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. Pain 2004;109:26-35.
30. Rodríguez MJ, Díaz S, Vera-Llonch M, Dukes E, Rejas J. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007;23:2585-96.
31. Johnston A, Hamandi K. Cost-effectiveness of pregabalin: A UK perspective. Expert Rev Pharmacoecon Outcomes Res 2007;7:327-33.
32. Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia: A Canadian perspective. Clin Ther 2006;28:1922-34.
33. Stolley PD, Laporte J. The public health, the university, and pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology, 3rd edition. New York: John Wiley & Sons; 2000:75-89.
34. Gallagher RM. Naturalistic study designs in samples with refractory pain: Advantages and limitations. Pain Med 2004;5:143-5.
35. Navarro A, Saldaña MT, Pérez C, Torrades S, Rejas J. Patient-reported-outcomes in subjects with neuropathic pain receiving pregabalin: Evidence from the medical practice in primary care settings. Pain Med 2010;11:719-31.
36. Perez C, Galvez R, Huelbes S, etal. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire dor differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes 2007;5:66.
37. Lázaro C, Caseras X, Whizar-Lugo VM, etal. Psychometric properties of a Sapanish version of the McGill Pain Questionnaire in several Spanish-speaking countries. Clin J Pain 2001;17:365-74.
38. The EuroQol Group. EuroQol-A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
39. Badía X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version of EuroQoL: A description and its applications. European Quality of Life scale. Med Clin (Barc) 1999;112(suppl 1):79-85.
40. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002;4:334-43.
41. Stewart WF, Lipton RB, Simon D. Work-related disability: Results from the American migrNSAIDs study. Cephalalgia 1996;16:231-8.
42. Catálogo de Especialidades Farmacéuticas 2006. Consejo General de Colegios Oficiales de Farmacéuticos, Madrid. 2006.
43. Oblikue. eSALUD. Base de datos de costes sanitarios. In: Social, S.C.d.E.e.E.d.l.S.y.P. (Ed.). SOIKOS, Barcelona. 2006.
44. Instituto Nacional de Estadística. Encuesta Trimestral de Coste Laboral. [Updated: 15/03/2006]. Available at: (accessed October 2, 2006).
45. Brooks R. EuroQoL: The current state of play. Health Policy 1996;37:53-72.
46. O'Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics 2008;26:1045-64.
47. O'Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc 2007;55:1176-84.